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LETTERS TO THE EDITORRegarding “Outcomes of covered versus bare-metal
balloon-expandable stents for aortoiliac occlusive
disease”
With interest we have read the paper by Humphries et al, who
have performed a retrospective cohort study comparing outcome
of bare-metal stents (BMSs) with balloon-expandable covered
(CBE) stents.1 They concluded that BMSs are superior to CBE
stents at 3 years in the treatment of aortoiliac occlusive disease.
This is in conﬂict with other studies, including the Covered Versus
Balloon Expandable Stent Trial (COBEST), which is the only pub-
lished randomized trial of CBE stents for aortoiliac occlusive dis-
ease to date, and another historical cohort study. Both showed
signiﬁcantly better results in terms of restenosis and reinterventions
in the use of CBE stents, especially in more complex lesions.2,3
There are a few points that might have biased the results of the
present study, both related to clinical decision making. First, the
choice of CBE stents or BMSs was decided on a case-by-case basis,
without describing why a certain stent was chosen. There were no
differences between groups in lesion length or TransAtlantic Inter-
Society Consensus (TASC) classiﬁcation, but that does not exclude
differences between groups. Factors such as occlusion vs stenosis
and the presence of mural thrombus or calciﬁcations are not
included in the TASC classiﬁcation. The more costly CBE stents
are regularly reserved for speciﬁc, often more complex indications
in which these CBE stents might have a beneﬁt above BMSs,
thereby justifying the use of these more expensive stents.
Second, and even more important, they have shown that the
primary patency was signiﬁcantly lower in the CBE stent group.
Loss of primary patency was deﬁned as any stent that underwent
reintervention to prevent thrombosis or any stent that thrombosed
primarily. The decision for reintervention was made, again and un-
fortunately, on a case-by-case basis. It seems reasonable to assume
that an indication for a reintervention on a focal edge stenosis to
preserve patency in an expensive CBE stent might have been
more attractive than reintervening in a patient with a diffuse in-
stent restenosis without clinical symptoms. This may have severely
affected the outcome of this study, and it was for that reason that
Diehm et al have suggested replacement of the term patency with
absence of binary restenosis and occlusion in endovascular studies, as
was done in the COBEST.3,4 This would have excluded the clinical
decision-making process as a bias and would have provided real ev-
idence on the performance of CBE stents vs BMSs.
In summary, the result of this study merely reﬂects the clinical
performance of these stents in this particular center, but we agree
with the authors that more randomized studies, such as the Dutch
DISCOVER trial, are indicated before the use of CBE stents is
considered standard care.5
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Our study concluded that the primary patency of bare-metal
stents (BMSs) is superior to that of covered balloon-expandable
(CBE) stents,1 although on the basis of the relatively small number
of patients evaluated, this may be an overstatement. Our work
describes the bias of vascular specialists to use BMSs rather than
CBE stents in treating aortoiliac occlusive disease and supports
the lack of sufﬁcient data to change this practice pattern. This
work is observational and has inherent biases, but vascular special-
ists are looking for guidance to support decision making. The
Covered Versus Balloon Expandable Stent Trial (COBEST),2
despite being a randomized controlled trial, does not answer the
question of when and for what lesions a CBE stent should be
chosen. COBEST has limitations, most notably the use of binary
restenosis as the primary end point, the vague criteria for deﬁning
restenosis, the absence of data on which imaging modalities were
used to diagnose the restenoses and how many of these restenoses
where conﬁrmed by angiography, and the lack of power for the
subgroup analyses that were performed.
When the design of the COBEST trial is considered, it is
important to remember that the trial was designed as a noninfer-
iority trial and that the only conclusion that can be drawn is that
CBE stents are no worse than BMSs for the outcome of binary
restenosis. Diehm et al3 have called for standardization of out-
comes and argued that restenosis be used as an outcome, rather
than patency. Restenosis allows comparison of the technical as-
pects of how stents perform head to head, but this is not neces-
sarily a meaningful outcome for patients. We do not need
another explanatory study to inform us of the safety and efﬁcacy
of covered stents. We need more pragmatic studies that look at
how these treatments perform in average patients and must face
the reality that decisions for reintervention are always made on
a case-by-case basis.
An additional limitation of COBEST is the lack of transpar-
ency in regard to conﬁrmation of stenosis. It has been well estab-
lished that in the carotid4 and mesenteric5 arteries, velocity criteria
to diagnose stenosis of stented arteries can be different from the
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not been validated for diagnosis of restenosis after iliac artery stent-
ing or stent grafting. No data are provided as to the distribution of
the diagnostic modalities used to diagnose the stenoses in COB-
EST, nor do the authors provide data on how many patients had
conﬁrmation of the restenosis by angiography.
Finally, COBEST did not stratify patients on the basis of the
TransAtlantic Inter-Society Consensus (TASC) classiﬁcation, and
more than 60% of the patients had TASC B disease. Therefore,
the study is underpowered to make any meaningful conclusion
for the post hoc analysis of patients with TASC C and D disease
where the authors indicated a difference in binary restenosis
between the two stents.
Our study and COBEST have clearly sparked interest.
The DISCOVER6 trial will use some of the same end points as
COBEST and will be underpowered for subgroup analyses. On
the other hand, the planned assessment of quality of life and
walking scores may help determine whether restenosis is an
outcome that is important to patients.
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Regarding “Interfacility transfer and mortality
for patients with ruptured abdominal aortic
aneurysm”
We were pleased to read the systematic analysis concerning
interfacility transfer and mortality for patients with ruptured
abdominal aortic aneurysm (rAAA) by Mell et al.1 We do disagree,
however, with the ﬁrst part of the discussion stating that their
actual study was the ﬁrst to describe population-level outcomes
for patients with rAAAs, including patients transferred for care.
Our analysis,2 published in 2012, is based on the entire populationof Norway and describes incidence, handling, and outcome for pa-
tients with rAAA in Norway, including those transferred to
another hospital before operative repair.
Interestingly, the proportions of patients transferred for treat-
ment of rAAA, as well as the proportions of patients who under-
went rAAA repair after transfer, are similar in both studies. The
former is 19.1% in their study compared with 17.9% (87 of 487)
in our study, the latter is 83.3% (706 of 847) in their study
compared with 86.2% (75 of 87) in our study.1,2
Both studies indicate that most patients with rAAA can still be
treated after transfer, which is good news, bearing in mind that
centralization of vascular services leaves transfer and a subsequent
operation as the only treatment option for a growing number of
patients. Optimizing transfer time and communication between
hospitals, including shared imaging, enabling preoperative prepara-
tion before the patient arrives, may improve results to a certain de-
gree. Nevertheless, there can be no doubt that screening for AAA
and elective operation will give much better results than even the
most efﬁcient transfer system for patients with rAAA and should be
implemented as soon as possible.3-5 The screening algorithm, how-
ever, may have to be adapted due to changing epidemiology.6
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Our study is the ﬁrst to describe population level outcomes in
the United States, and we appreciate the references provided by Dr
Altreuther describing a European experience. It is noteworthy that
the ﬁndings of both studies are quite similar, despite differences in
health care delivery systems, geography, and distances. We also
agree that the best treatment for ruptured abdominal aortic aneu-
rysm (rAAA) is prevention, with early detection and effective sur-
veillance.1,2 For those who present with rAAA and cannot receive
treatment at the initial presenting facility, we found that the ben-
eﬁts of transfer for repair appear to be eclipsed by those who die
en route or after arrival to the receiving hospital without receiving
